Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

BACKGROUND: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Fa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circulation
Hlavní autoři: Kosiborod, Mikhail N., Jhund, Pardeep S., Docherty, Kieran F., Diez, Mirta, Petrie, Mark C., Verma, Subodh, Nicolau, Jose C., Merkely, Béla, Kitakaze, Masafumi, DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Solomon, Scott D., Bengtsson, Olof, Lindholm, Daniel, Niklasson, Anna, Sjöstrand, Mikaela, Langkilde, Anna Maria, McMurray, John J.V.
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2020
Témata:
Original Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964869/
https://ncbi.nlm.nih.gov/pubmed/31736335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.044138
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky